Topics

Roche cancer drug the 3rd approved for pan-tumor use

13:41 EDT 15 Aug 2019 | BioPharmaDive

Entrectinib, which will be sold as Rozlytrek, joins Bayer's Vitrakvi as a treatment for solid cancers featuring a rare genetic fusion.

Original Article: Roche cancer drug the 3rd approved for pan-tumor use

NEXT ARTICLE

More From BioPortfolio on "Roche cancer drug the 3rd approved for pan-tumor use"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...